Recent abolon transactions
Amethyst Radiotherapy Raises € 300m of Growth Financing from Ares
In a significant stride towards enhancing access to advanced cancer treatment, Amethyst Radiotherapy Group has secured a landmark €300 million financing agreement with Credit funds managed by Ares Management Corporation (“Ares”), a leading global alternative investment manager. This investment positions Amethyst as a leading player in the European oncology sector, as it continues to accelerate its expansion. The facilities secured will support strategic acquisitions and capacity enhancement, positioning Amethyst firmly among the frontrunners to redefine the European cancer treatment landscape. Abolon’s prepared the commercial vendor due diligence of Amethyst for the successful refinancing, highlighting once more Abolon’s strong expertise in diagnosing and treating oncological diseases. With separate teams, Abolon advises clients on corporate and financing transactions incl. commercial due diligence, vendor due diligence, strategy development and M&A/corporate finance. Our clients benefit from our experience after more than 200 C(V)DD projects and M&A transactions.
Healthcare insights
How will new landmark legislation affect Germany’s private hospital groups
The new Hospital Structure Act could force small, low quality public sector hospitals to the wall. But it could also cap growth for big private operators. We examine likely scenarios.
Healthcare deal of the month
December 2015: Etac acquires Convaid
The Deal: In December 2015, Etac, a Sweden-based developer and manufacturer of mobility solutions and rehab products, acquired Convaid Products
WELCOME TO ABOLON
Abolon is a strategy consulting and corporate finance company with an exclusive focus on the healthcare sector.
We pride ourselves on our specialist insights into the various segments of the healthcare markets in Europe and beyond.
Our global network in the healthcare sector provides us with unmatched dealflow of large and mid-sized healthcare opportunities.
